A Bengaluru CEO experienced severe nosebleeds linked to dangerously high blood pressure after having no previous symptoms.

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...

The most common adverse events with sotatercept were epistaxis and telangiectasia. This article was published on March 31, 2025, at NEJM.org. A data sharing statement provided by the authors is ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...

Genmab A/S announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult ...

There was evidence of a smooth periosteal reaction associated with the cranial and caudal cortex of the proximal humerus of ...